Vivani Medical

Vivani Medical

Yahoo Finance • 3 days ago

Novo Nordisk (CPSE:NOVO B) Could Be 13% Overvalued Following Its Vivani Deal

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Vivani Medical's new agreement gives Novo Nordisk (CPSE:NOVO B) ac... Full story

Yahoo Finance • 5 days ago

Novo Nordisk (CPSE:NOVO B) Teams Up With Vivani To Test A Semaglutide Implant

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Novo Nordisk and Vivani Medical are collaborating to evaluate a semaglutide drug implant using Viv... Full story

Yahoo Finance • 5 days ago

Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

ALAMEDA, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, ultra long-acting drug implants, today announced the signing o... Full story

Yahoo Finance • 10 days ago

Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.

Vivani proposes to merge Cortigent, Inc. with a wholly owned subsidiary of ClearOne, Inc. (Nasdaq: CLRO), and change the listed company’s name and ticker to Cortigent Holdings, Inc. (d/b/a Cortigent) and “CRGT” Cortigent is a leading deve... Full story

Yahoo Finance • 16 days ago

Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker

ALAMEDA, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the app... Full story

Yahoo Finance • 17 days ago

Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management

ALAMEDA, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that it... Full story

Yahoo Finance • 20 days ago

Vivani Medical CEO Adam Mendelsohn to Present at the 2026 BIO International Convention

ALAMEDA, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CE... Full story

Yahoo Finance • 2 months ago

Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update

Initiation of SLIM-1™ clinical trial, a Phase 1 study of NPM-139, a semaglutide implant under development for chronic weight management, on track for mid-year 2026 $28 million in cash, cash equivalents, restricted cash and capital commitm... Full story

Yahoo Finance • 3 months ago

Vivani Medical price target lowered to $3.50 from $4 at H.C. Wainwright

H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Vivani Medical (VANI) to $3.50 from $4 and keeps a Buy rating on the shares after the company recently reported its 2025 results, citing an increased share count for the fi... Full story

Yahoo Finance • 4 months ago

Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Successful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept data for a semaglutide implant advance NPM-139, miniature, ultra long-acting semaglutide implant under development for chronic weight managem... Full story

Yahoo Finance • 5 months ago

Least shorted stocks with up to $2B market cap as of mid-February

[short sale] abluecup Short sellers are largely absent from a group of small- and mid-cap stocks where short interest hovers around just 0.5%, signaling limited bearish conviction across a diverse mix of sectors. The least-shorted names... Full story

Yahoo Finance • 8 months ago

Vivani Medical Provides Business Update and Reports Third Quarter 2025 Financial Results

Company plans to initiate Phase 1 clinical study of semaglutide implant for chronic weight management in the first half of 2026 and parallel investments in studies to enable rapid initiation of Phase 2 dose-ranging study, pending Phase 1 r... Full story

Yahoo Finance • 8 months ago

Vivani Medical, Inc. Announces Closing of Common Stock Offering

ALAMEDA, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the clo... Full story

Yahoo Finance • 8 months ago

Vivani Medical prices $16M offering at $1.62 per share

* Clinical-stage biopharmaceutical company Vivani Medical (NASDAQ:VANI [https://seekingalpha.com/symbol/VANI]) priced [https://seekingalpha.com/pr/20279638-vivani-medical-inc-announces-pricing-of-common-stock-offering] a registered direc... Full story

Yahoo Finance • 9 months ago

Vivani Medical, Inc. Announces Pricing of Common Stock Offering

ALAMEDA, Calif., Oct. 26, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the pri... Full story

Yahoo Finance • 9 months ago

Vivani Medical Withdraws Record Date for Cortigent Neuromodulation Subsidiary Spin-Off

ALAMEDA, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that th... Full story

Yahoo Finance • 10 months ago

Vivani Medical to Present at the Emerging Growth Conference on September 25, 2025

ALAMEDA, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that i... Full story

Yahoo Finance • 10 months ago

Presenting on Emerging Growth Conference 86 Day 2 September 25; Register to live stream

MIAMI, Sept. 24, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 86th Emerging Growth Conference on September 24 & 25, 2025. The Emerging Growth Conference identifie... Full story

Yahoo Finance • 10 months ago

Presenting on Emerging Growth Conference 86 Day 1 on September 24; Register to live stream

MIAMI, Sept. 23, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 86th Emerging Growth Conference on September 24 & 25, 2025. The Emerging Growth Conference identifie... Full story

Yahoo Finance • 10 months ago

Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders

Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind Cortigent’s ne... Full story